| ¿µ¹® | retinal detachment | ÇÑ±Û | ¸Á¸· ¹Ú¸® |
|---|---|---|---|
| ¼³¸í | Ä«¸Þ¶ó¿¡ ÀÖ¾î¼ Çʸ§¿¡ ÇØ´çÇÏ´Â ´«ÀÇ ¸Á¸·Àº Å©°Ô µÎ °³ÀÇ ÃþÀ¸·Î ³ª´ ¼ö°¡ ÀÖ´Ù. ¾ÈÂÊ¿¡ ÀÖ´Â ½ÇÁ¦ÀÇ ºûÀ» °¨ÁöÇÏ´Â °¨°¢Ãþ°ú ¹Ù±ùÂÊÀÇ ¿ÜºÎÀÇ ºûÀ» Â÷´ÜÇÏ´Â »ö¼Ò»óÇÇÃþÀÌ ±×°ÍÀε¥ ±× »çÀÌ¿¡´Â ÀáÀçÀûÀÎ °ø°£ÀÌ ÀÖ¾î¼ ¶³¾îÁö±â°¡ ½±´Ù. ÀÌ »çÀ̰¡ ¶³¾îÁö¸é ¸Á¸·ÀÇ °¨°¢ÃþÀÌ ¸Á¸·ÀÇ »ö¼Ò»óÇÇÃþ°ú ºÐ¸®µÇ´Âµ¥ À̰ÍÀ» ¸Á¸·¹Ú¸®¶ó°í ÇÑ´Ù. ÀÌ ¸Á¸·ÀÇ ¹Ú¸®¿¡´Â ¿©·¯ °¡Áö ¿øÀÎÀÌ ÀÖÁö¸¸ °¨°¢ÃþÀÇ ¸Á¸·¿¡ ÀÛÀº ±¸¸ÛÀÎ ¿°ø(break)¿¡ ÀÇÇØ¼ ±×°÷À¸·Î ´«¼ÓÀ» ä¿ì°í ÀÖ´Â ¾×ü°¡ Èê·¯ µé¾î°¡¼ »ý±â´Â ¸Á¸·ÀÇ ¹Ú¸®¸¦ ¿°ø¼º ¸Á¸·¹Ú¸®(rhegmatogenous retinal detachment)¶ó Çϰí, ¾È±¸ÀÇ º´ÅÍ¿¡ ÀÇÇØ¼ ¾È±¸³»¿¡ ¼¶À¯Á¶Á÷ÀÌ »ý±â°í ±×°ÍÀÌ ¸Á¸·ÀÇ °¨°¢ÃþÀ» Àâ¾Æ ²ø¾î¼ ¸Á¸·ÀÌ ¹Ú¸®µÇ´Â °ßÀμº ¸Á¸·¹Ú¸®(traction retinal detachment) ¹× ¸Á¸·ÀÇ 2°³ÀÇ Ãþ¿¡ »ïÃâ¾×ÀÌ ±«¾î¼ »ý±â´Â »ïÃ⼺ ¸Á¸·¹Ú¸®(exudative retinal detachment) µî ¿°ø¿¡ ÀÇÇØ¼ »ý±â´Â ¸Á¸·¹Ú¸®°¡ ¾Æ´Ñ °ÍÀ» ºñ¿°ø¼º ¸Á¸·¹Ú¸®(nonrhegmatogenous retinal detachment)¶ó°í ¸»ÇÑ´Ù. |
||
| ¿µ¹® | hypertension | ÇÑ±Û | °íÇ÷¾Ð |
|---|---|---|---|
| ¼³¸í | µ¿¸ÆÀÇ Ç÷¾ÐÀÌ ³ôÀº °Í. ÀϹÝÀûÀ¸·Î ¸»ÇÏ´Â °íÇ÷¾ÐÀº ÀÌ µ¿¸Æ¼º °íÇ÷¾ÐÀ» ¸»ÇÑ´Ù. Ç÷¾ÐÀ̶õ Ç÷°ü¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÏ´Â °ÍÀ¸·Î ´ë°³ ƯÀÌÇÑ ¼³¸íÀÌ ¾øÀ¸¸é µ¿¸ÆÀÇ ¾Ð·ÂÀ» ¸»ÇÑ´Ù. Ç÷¾Ð¿¡´Â ¼öÃà±âÇ÷¾Ð°ú À̿ϱâÇ÷¾ÐÀÌ ÀÖ´Ù. ¼öÃà±âÇ÷¾ÐÀ̶õ ½ÉÀåÀÌ ¼öÃàÇÒ ¶§ÀÇ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϰí À̿ϱâ Ç÷¾ÐÀ̶õ ½ÉÀåÀÌ ÀÌ¿ÏÇÒ °æ¿ì¿¡ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÑ´Ù. ´ç¿¬È÷ ¼öÃà±â Ç÷¾ÐÀÌ À̿ϱâ Ç÷¾Ðº¸´Ù ³ô´Ù. Ç÷¾ÐÀ» ¸»ÇÒ ¶§¿¡ 120/80À̶ó°í Àû´Â °ÍÀÇ ¾ÕÀÇ °ÍÀº ¼öÃà±â Ç÷¾ÐÀ» ÀǹÌÇÏ°í µÚ¿¡ Àû´Â 80Àº À̿ϱâ Ç÷¾ÐÀ» ÀǹÌÇÑ´Ù. °íÇ÷¾ÐÀº ÁÖ·Î À̿ϱâÀÇ Ç÷¾ÐÀ» ±âÁØÀ¸·Î Á¤ÇÑ´Ù. ¿©·¯ °¡Áö ±âÁØÀÌ ÀÖÀ¸³ª À̿ϱâ Ç÷¾ÐÀÌ 90mmHgÀÌ»óÀÎ °æ¿ì¸¦ ¸»ÇÑ´Ù. °íÇ÷¾Ð ÀÚü¿¡ ÀÇÇÑ Áõ»óÀº º°·Î ¾ø´Ù. ´Ù¸¸ °íÇ÷¾Ð¿¡ ÀÇÇÑ ÇÕº´Áõ°ú µ¿¸Æ°æÈÀÇ ÃËÁø¿¡ ÀÇÇØ º´¹ßÇÏ´Â Áúȯ¿¡ ÀÇÇÏ¿© Áõ»óÀÌ »ý±ä´Ù. °íÇ÷¾Ð¿¡ ÀÇÇÑ ÇÕº´ÁõÀº ´ë°³ Ç÷°ü¿¡ °É¸®´Â °úµµÇÑ ¾Ð·ÂÀ¸·Î ÀÎÇÑ Ç÷°üÀÇ ¼Õ»óÀÌ Áß¿äÇÑ ¿øÀÎÀÌ´Ù. °íÇ÷¾ÐÀº µ¿¸Æ°æÈÀÇ ÁÖ¿ä À¯¹ßÀÎÀÚ ÁßÀÇ ÇϳªÀÌ´Ù. µ¿¸Æ°æÈ´Â µ¿¸ÆÀÇ º®ÀÌ µÎÅÍ¿öÁö°í µ¿¸ÆÀÌ Åº·ÂÀ» ÀÒ¾î¹ö¸®´Â ÁúȯÀÌ´Ù. ¾î¶² µ¿¸ÆÀÌ µ¿¸Æ°æÈ¿¡ °É¸®¸é ÀÌ µ¿¸ÆÀº µÎÅÍ¿öÁø Ç÷°üº®¿¡ ÀÇÇØ¼ ³»°æÀÌ ÀÛ¾ÆÁö°Ô µÈ´Ù. ÀÌ·¸°Ô µÇ¸é ±× µ¿¸ÆÀ¸·ÎºÎÅÍ Ç÷¾×À» °ø±Þ¹Þ´ø Àå±â´Â Ç÷¾×À» Àû°Ô °ø±Þ¹Þ°Ô µÇ°í ±× Á¤µµ°¡ ½ÉÇÏ°Ô µÇ¸é ±× Àå±â´Â °á±¹ ¼Õ»óÀ» ÀÔ°Ô µÈ´Ù. µ¿¸Æ°æÈ·Î ÀÎÇÑ Áúº´ÀÇ ´ëÇ¥ÀûÀÎ ¿¹´Â ½ÉÀåÀÇ ±ÙÀ°¿¡ Ç÷¾×À» °ø±ÞÇÏ´Â ½ÉÀ嵿¸Æ¿¡ µ¿¸Æ°æÈÀÇ º¯È°¡ ¿À´Â ½ÉÀ嵿¸Æº´ÀÌ´Ù. °íÇ÷¾ÐÀÇ Ä¡·á¿¡ ¾²ÀÌ´Â ¾à¹°Àº ´ÙÀ½°ú °°Àº °ÍÀÌ ÀÖ´Ù. -ÀÌ´¢Á¦-ÄáÆÏ¿¡¼ ¼öºÐ°ú ÀüÇØÁúÀÇ ¹èÃâÀ» ÃËÁø½ÃŰ´Â ¾à¹°. ü³»ÀÇ ¼öºÐÀÇ ¾çÀ» °¨¼Ò½ÃÄѼ Ç÷¾×ÀÇ È帣´Â ¾çÀ» Àû°ÔÇÏ°í ¶Ç Ç÷°üÁÖÀ§ Á¶Á÷ÀÇ ¼öºÐÀÇ °¨¼Ò·Î Ç÷°üÀ» È®Àå½ÃŰ´Â ¿ªÇÒ(Ç÷°üÀÌ ÀÖ°í ±× Ç÷°üÀ» ½×°í ÀÖ´Â Á¶Á÷¿¡ ¼öºÐÀÌ Â÷ ÀÖÀ¸¸é ±× Á¶Á÷ÀÌ Ç÷°üÀ» ´·¯¼ Ç÷°üÀÌ È®ÀåÇÏ´Â °ÍÀ» ¹æÇØÇÑ´Ù)·Î Ç÷¾ÐÀ» °¨¼Ò½ÃŲ´Ù. -Ä®½·-Åë·ÎÂ÷´ÜÁ¦£¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡´Â Ä®½·ÀÌ ÇÊ¿äÇÏ´Ù. Áï Ç÷°üÀÇ ¼öÃà¿¡ °ü¿©ÇÏ´Â Ç÷°üµµ ¿ª½Ã ¼öÃàÀ» À§Çؼ´Â Ä®½·ÀÌ ÇÊ¿äÇÏ´Ù. Ä®½·-Åë·ÎÂ÷´ÜÁ¦´Â ±ÙÀ°¼¼Æ÷ ¼ÓÀ¸·Î Ä®½·ÀÌ µé¾î°¡´Â °ÍÀ» ¹æÁöÇØ¼ Ç÷°ü±ÙÀ°ÀÇ ¼öÃàÀ» ¹æÇØÇϰí ÀÌ·Î ÀÎÇØ¼ Ç÷°üÀÇ È®ÀåÀ» À¯µµÇÑ´Ù. -¾ËÆÄÂ÷´ÜÁ¦, º£Å¸Â÷´ÜÁ¦-Ç÷°üÀº ÀÚÀ²½Å°æ°èÀÇ Áö¹è¸¦ ¹Þ´Â´Ù. ±×Áß¿¡¼µµ Ç÷°üÀº ±³°¨½Å°æÀÇ ¿µÇâ¿¡ ÀÇÇØ¼ ¼öÃà°ú ÀÌ¿ÏÀ» ÇÑ´Ù. ±³°¨½Å°æÀÇ ÀÛ¿ëÀº ±× ¼ö¿ëü¿¡ µû¶ó ´Þ¶óÁø´Ù. ±³°¨½Å°æÀÇ ¼ö¿ëüÀÇ Á¾·ù¿¡´Â ¾ËÆÄ¼ö¿ëü¿Í º£Å¸¼ö¿ëü°¡ ÀÖ´Ù. Ç÷°üÀ» Áö¹èÇϰí ÀÖ´Â ±³°¨½Å°æ¿¡¼ ¾ËÆÄ¼ö¿ëü´Â Ç÷°üÀÇ ¼öÃàÀ» ÀÏÀ¸Å°°í º£Å¸¼ö¿ëü´Â Ç÷°üÀÇ È®ÀåÀ» ÀÏÀ¸Å²´Ù. ±×·¯¹Ç·Î ¾ËÆÄ¼ö¿ëüÀÇ ÀÛ¿ëÀ» ¸·´Â °æ¿ì¿¡ Ç÷°üÀÇ È®ÀåÀ» À¯µµÇÒ ¼ö ÀÖ°í º£Å¸-¼ö¿ëüÀÇ ÀÛ¿ëÀ» Ç×Áø½Ãų °æ¿ì¿¡ ¿ª½Ã Ç÷°üÀÇ È®Á¤À» À¯µµÇÒ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | renal hypertension | ÇÑ±Û | ÄáÆÏ¼º°íÇ÷¾Ð |
|---|---|---|---|
| ¼³¸í | ÄáÆÏ½ÇÁúÀÇ º´º¯À¸·Î ÀÎÇØ ¾ß±âµÈ °íÇ÷¾Ð. ÄáÆÏÀÇ ´ëÇ¥Àû ±â´ÉÀº ³ëÆó¹° ¹× ¼öºÐÀÇ ¹è¼³ÀÌ´Ù. ±×·±µ¥ ÀÌ·¯ÇÑ ÄáÆÏ±â´É¿¡ ÀÌ»óÀÌ »ý°åÀ» °æ¿ì ü³»¿¡ °úÀ×¼öºÐÀÇ ÃàÀûÀÌ ¹ß»ýÇÏ°Ô µÈ´Ù. À̿Ͱ°Àº °úÀ×¼öºÐÀÇ ÃàÀûÀº Ç÷°ü³» Á¤¼ö¾ÐÀ» »ó½Â½ÃÄÑ °íÇ÷¾ÐÀ» À¯¹ßÇÏ°Ô µÈ´Ù. Ä¡·á´Â ¿øÀÎ ÄáÆÏº´ÀÇ ±³Á¤À̸ç ÀÌÀ¯¸¦ ¸ð¸£´Â ¿ø¹ß°íÇ÷¾Ð°ú ´Þ¸® ÄáÆÏ¼º°íÇ÷¾ÐÀÇ °æ¿ì¿¡´Â ¿øÀÎ ÄáÆÏº´ÀÌ ±³Á¤µÇ¸é °íÇ÷¾Ðµµ »ç¶óÁö°Ô µÈ´Ù. |
||
| KW change | Keith Wagener change |
|---|---|
| RD | radial deviation; radiology department; rate difference; Raynaud disease; reaction of degeneration; ... |
| JVP | [POMD P 49 - 52] 1) Jugular Vein Pressure 2) Jugular Venous Pulse ... |
| IPH | idiopathic portal hypertension; idiopathic pulmonary hemosiderosis; idiopathic pulmonary hypertensio... |
| PHT | phenytoin; portal hypertension; primary hyperthyroidism; pulmonary hypertension |
| STOP Hypertension | Swedish Trial in Old Patients with Hypertension |
|---|---|
| CGI-C | Clinical Global Impression of Change |
| FAC | Fractional area change |
| HSC | Health System Change |
| MCD | Minimal change disease |
| Armanni-Ebstein change | Glycogen vacuolization of the loops of Henle, seen in diabetics before the introduction of insulin. Synonym: Armanni-Ebstein change. (05 Mar 2000) |
|---|---|
| Baggenstoss change | Distention of pancreatic acini by proteinaceous secretion, seen in dehydration. (05 Mar 2000) |
| change | An alteration; in pathology, structural alteration of which the cause and significance is uncertain. Synonym: shift. (05 Mar 2000) |
| change of life | Colloquialism for menopause, climacteric. (05 Mar 2000) |
| chemical change | A process in which one or more substances are changed into one or more different substances. (09 Oct 1997) |
| minimal-change disease | <nephrology> A disorder of the kidneys which largely affects the glomerulus, the blood filtering structure. This disorder is one common cause of nephrotic syndrome, minimal glomerular changes, in children affecting 2 to 3 children per 100,000 population under age 16 in the USA. Minimal change disease is also seen rarely in adults. The cause is unknown but may be related to an autoimmune illness. It is marked by oedema, albuminuria, and an increase in cholesterol in the blood, but otherwise with fairly good renal function. Tubular epithelium is vacuolated by cholesterol droplets, but the glomeruli show only that the foot processes of the glomerular epithelial cells are fused, probably secondary to the proteinuria; the cause of the increased glomerular permeability to plasma protein is unknown. Risk factors include a history for a immune disorder, recent immunisation or a bee sting. Diagnosis is made by renal biopsy. Treatment include systemic corticosteroids which are usually quite effective in curing this disease. Other medications include chlorambucil and cyclophosphamide. In most cases, a moderate protein diet (1 gram protein per Kg body weight per day) will be recommended. Salt (sodium) restriction can be helpful to reduce swelling and vitamin D is usually supplemented. Synonym: lipoid nephrosis (27 Sep 1997) |
| minimal-change nephrotic syndrome | <nephrology> A disorder of the kidneys which largely affects the glomerulus, the blood filtering structure. This disorder is one common cause of nephrotic syndrome, minimal glomerular changes, in children affecting 2 to 3 children per 100,000 population under age 16 in the USA. Minimal change disease is also seen rarely in adults. The cause is unknown but may be related to an autoimmune illness. It is marked by oedema, albuminuria, and an increase in cholesterol in the blood, but otherwise with fairly good renal function. Tubular epithelium is vacuolated by cholesterol droplets, but the glomeruli show only that the foot processes of the glomerular epithelial cells are fused, probably secondary to the proteinuria; the cause of the increased glomerular permeability to plasma protein is unknown. Risk factors include a history for a immune disorder, recent immunisation or a bee sting. Diagnosis is made by renal biopsy. Treatment include systemic corticosteroids which are usually quite effective in curing this disease. Other medications include chlorambucil and cyclophosphamide. In most cases, a moderate protein diet (1 gram protein per Kg body weight per day) will be recommended. Salt (sodium) restriction can be helpful to reduce swelling and vitamin D is usually supplemented. Synonym: lipoid nephrosis (27 Sep 1997) |
| conformational change | <cell biology> Alteration in the shape usually the tertiary structure of a protein as a result of alteration in the environment pH, temperature, ionic strength) or the binding of a ligand (to a receptor) or binding of substrate (to an enzyme). (18 Nov 1997) |
| Crooke's hyaline change | Replacement of cytoplasmic granules of basophil cells of the anterior pituitary by homogenous hyaline material; a characteristic finding in Cushing's syndrome, but usually not present in the cells of a basophil adenoma. Synonym: Crooke's hyaline degeneration. (05 Mar 2000) |
| social change | Social process whereby the values, attitudes, or institutions of society, such as education, family, religion, and industry become modified. It includes both the natural process and action programs initiated by members of the community. (12 Dec 1998) |
| enthalpy change | <chemistry> In a reaction, this is more or less equal to the difference between the energy put into breaking bonds and the enery gained from new bond formation. (13 Oct 1997) |
| epigenetic change | <biology> Any changes in an organism brought about by alterations in the action of genes are called epigenetic changes. Epigenetic transformation refers to those processes which cause normal cells to become tumour cells without the occurrence of any mutations. (07 May 1998) |
| fatty change | The appearance of microscopically visible droplets of fat in the cytoplasm of cells. See: fatty degeneration. Synonym: fatty change. (05 Mar 2000) |
| life change events | Those occurrences, including social, psychological, and environmental, which require an adjustment or effect a change in an individual's pattern of living. (12 Dec 1998) |
| accelerated hypertension | <cardiology> A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure. Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension. (27 Sep 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|